|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
After looking at Aviragen Therapeutics Inc’s (NASDAQ:VXRT) latest earnings update (31 December 2017), I found it helpful to revisit the company’s performance in the past couple of years and compareRead More...
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it has reached an understanding with the CAS Group under which East Hill, a major shareholder in Aviragen, will support the merger between Vaxart and Aviragen.
SUWANEE , Ga. and PETERBOROUGH, N.H. , Feb. 9, 2018 /PRNewswire/ -- Digirad Corporation, East Hill Management Company, LLC, and Thomas M. Clay (collectively with certain other participants in the solicitation, ...
CAS Group Supports the BTA074 Program and Considers it a Valuable Asset of Aviragen Glass Lewis Recommends Stockholders Vote AGAINST the Proposed Merger with Vaxart SUWANEE , Ga. and PETERBOROUGH, N.H. ...
TERMS OF DEAL UNJUSTIFIED: ISS States That "AVIR Shares Currently Trade at a Small Fraction of the Company's Implied Post-Merger Valuation, which Seems to Indicate that Management has Not Made a Sufficiently ...
Believes the Proposed Merger with Vaxart is Not in the Best Interests of AVIR Stockholders SUWANEE , Ga. and PETERBOROUGH, N.H. , Jan. 24, 2018 /PRNewswire/ -- Digirad Corporation, East Hill Management ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aviragen Therapeutics, Inc. Here are 5 ETFs with the largest exposure to AVIR-US. Comparing the performance and risk of Aviragen Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)